127 related articles for article (PubMed ID: 6417867)
21. The effects of two gonane progestins alone and in combination with ethinyl estradiol on serum lipoproteins.
Crona N; Silfverstolpe G; Samsioe G
Eur J Obstet Gynecol Reprod Biol; 1985 Jun; 19(6):365-74. PubMed ID: 3160616
[TBL] [Abstract][Full Text] [Related]
22. Coronary heart disease risk markers in users of low-dose oral contraceptives.
Godsland IF; Crook D; Wynn V
J Reprod Med; 1991 Mar; 36(3 Suppl):226-37. PubMed ID: 2046076
[TBL] [Abstract][Full Text] [Related]
23. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
Hirvonen E; Mälkönen M; Manninen V
N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the effects of NORPLANT capsules and NORPLANT-2 rods on clinical chemistry: metabolic changes.
Singh K; Viegas OA; Ratnam SS
Ann Acad Med Singap; 1990 Nov; 19(6):833-6. PubMed ID: 2130749
[TBL] [Abstract][Full Text] [Related]
25. Serum lipid profile in women using levonorgestrel contraceptive implant, Norplant-2.
Dash DS; Das S; Nanda U; Tripathy BB; Samal KC
Contraception; 1988 Apr; 37(4):371-82. PubMed ID: 3133159
[TBL] [Abstract][Full Text] [Related]
26. Different effects of two progestins on plasma high density lipoprotein (HDL2) and postheparin plasma hepatic lipase activity.
Tikkanen MJ; Nikkilä EA; Kuusi T; Sipinen S
Atherosclerosis; 1981; 40(3-4):365-9. PubMed ID: 6460509
[TBL] [Abstract][Full Text] [Related]
27. The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol.
Roy S; Krauss RM; Mishell DR; Casagrande J; Pike MC
Contraception; 1981 Oct; 24(4):429-49. PubMed ID: 6797785
[TBL] [Abstract][Full Text] [Related]
28. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
29. The effect of D-norgestrel, 30 micrograms, on the oral glucose tolerance test, including insulin levels, in Thai women.
Vongvinyoutragan S; Matangkasombut O; Poshyachinda V; Dusitsin N; Tankeyoon M; Israngkun P; Chaudhury RR
Fertil Steril; 1976 May; 27(5):523-7. PubMed ID: 1278455
[TBL] [Abstract][Full Text] [Related]
30. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
31. Effect of Norplant implants on liver, lipid and carbohydrate metabolism.
Singh K; Viegas OA; Loke DF; Ratnam SS
Contraception; 1992 Feb; 45(2):141-53. PubMed ID: 1559336
[TBL] [Abstract][Full Text] [Related]
32. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
33. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins.
Otubu JA; Towobola OA; Aisien AO; Ogunkeye OO
Contraception; 1993 Feb; 47(2):149-59. PubMed ID: 8449015
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein patterns in women in Santo Domingo using a levonorgestrel/estradiol contraceptive ring.
Robertson DN; Alvarez F; Sivin I; Brache V; Stern J; Leon P; Faundes A
Contraception; 1981 Oct; 24(4):469-80. PubMed ID: 6797787
[TBL] [Abstract][Full Text] [Related]
35. Influence of a levonorgestrel-containing contraceptive vaginal ring on plasma lipids and lipoproteins in cynomolgus monkeys.
Adams MR; Rudel LL; Clarkson TB; Nelson CA; Thau RB; Moo-Young AJ
Contraception; 1983 Sep; 28(3):253-66. PubMed ID: 6416747
[TBL] [Abstract][Full Text] [Related]
36. Effects of daily 30 MCG norgestrel on glucose, insulin, cholesterol and triglycerides during 1 year's time of use.
Boonsiri B; Virutamasen P; Tangkeo P; Wongsrichanalai C
Asia Oceania J Obstet Gynaecol; 1983 Jun; 9(2):180-4. PubMed ID: 6351820
[TBL] [Abstract][Full Text] [Related]
37. Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes.
Skouby SO; Kühl C; Mølsted-Pedersen L; Petersen K; Christensen MS
Am J Obstet Gynecol; 1985 Nov; 153(5):495-500. PubMed ID: 3933351
[TBL] [Abstract][Full Text] [Related]
38. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
Lepot MR; Gaspard UJ
Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
[TBL] [Abstract][Full Text] [Related]
39. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel.
Holma P; Robertson DN
Contraception; 1985 Aug; 32(2):163-71. PubMed ID: 3935372
[TBL] [Abstract][Full Text] [Related]
40. Release rates of levonorgestrel from Silastic capsules, homogeneous rods and covered rods in humans.
Robertson DN; Sivin I; Nash HA; Braun J; Dinh J
Contraception; 1983 May; 27(5):483-95. PubMed ID: 6411428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
